// App-Quantinova.ai

TPS4580 : Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.

Researchers

Presenter

  • James M. G. Larkin

Principal Investigators

  • Michael S. Gordon

  • Fiona Thistlethwaite

  • Paul D. Nathan

  • Brian I. Rini

  • Marcella Martignoni

  • Michael Shnaidman

  • Chiara Chiruzzi

  • Alessandra Di Pietro

  • Toni K. Choueiri

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Pinnacle Oncology Hematology/HonorHealth Research Institute, Scottsdale, AZ

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Pfizer Inc, New York, NY

  • Pfizer Inc, New York, NY

  • Dana-Farber/Brigham and Women's Cancer Center, Boston, MA

Locations

  • United States

  • United Kingdom

Companies

  • PharmAbcine Inc.

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Avelumab

  • Sunitinib

  • Inlyta

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • III

Study Id's

  • NCT02493751

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved